throbber
HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`ONGLYZA safely and effectively. See full prescribing information for
`ONGLYZA.
`
`ONGLYZA (saxagliptin) tablets, for oral use
`Initial U.S. Approval: 2009
`
`
` --------------------------- INDICATIONS AND USAGE --------------------------
`ONGLYZA is a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an
`adjunct to diet and exercise to improve glycemic control in adults with type 2
`diabetes mellitus in multiple clinical settings. (1.1, 14).
`Limitation of use:
`Should not be used for the treatment of type 1 diabetes mellitus or
`•
`diabetic ketoacidosis (1.2).
`Has not been studied in patients with a history of pancreatitis (1.2, 5.1)
`
` ---------------------- DOSAGE AND ADMINISTRATION ----------------------
`Recommended dosage is 2.5 mg or 5 mg once daily taken regardless of
`•
`meals. (2.1)
`Patients with moderate or severe renal impairment, or end-stage renal
`disease (CrCl ≤ 50 mL/min): Recommended dosage is 2.5 mg once daily
`regardless of meals. (2.2)
`Assess renal function before starting ONGLYZA and periodically
`thereafter. (2.2)
`2.5 mg daily is recommended for patients also taking strong cytochrome
`P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole). (2.3, 7.1)
`
` --------------------- DOSAGE FORMS AND STRENGTHS --------------------
`Tablets: 5 mg and 2.5 mg (3)
`•
`
`•
`
`•
`
`•
`
`•
`
`
` ------------------------------ CONTRAINDICATIONS -----------------------------
`History of a serious hypersensitivity reaction (e.g., anaphylaxis,
`•
`angioedema, exfoliative skin conditions) to ONGLYZA. (4)
`
` ----------------------- WARNINGS AND PRECAUTIONS ----------------------
`Acute Pancreatits (postmarketing reports): If pancreatitis is suspected,
`•
`promptly discontinue ONGLYZA. (5.1)
`Hypoglycemia: In add-on to sulfonylurea, add-on to insulin, and add-on
`to metformin plus sulfonylurea trials, confirmed hypoglycemia was
`
`•
`
`more common in patients treated with ONGLYZA compared to placebo.
`When used with an insulin secretagogue (e.g., sulfonylurea) or insulin, a
`lower dose of insulin secretagogue or insulin may be required to
`minimize the risk of hypoglycemia. (5.2, 6.1)
`Hypersensitivity-Related Events (e.g., urticaria, facial edema): More
`common in patients treated with ONGLYZA than in patients treated
`with placebo; and postmarketing reports of serious hypersensitivity
`reactions such as anaphylaxis, angioedema, and exfoliative skin
`conditions. Promptly discontinue ONGLYZA, assess for other potential
`causes, institute appropriate monitoring and treatment, and initiate
`alternative treatment for diabetes. (5.3, 6.1, 6.2)
`Arthralgia: Severe and disabling arthralgia has been reported in patients
`taking DPP4 inhibitors. Consider as a possible cause for severe joint
`pain and discontinue drug if appropriate. (5.4)
`There have been no clinical studies establishing conclusive evidence of
`macrovascular risk reduction with ONGLYZA or any other antidiabetic
`drug (5.5)
`
`•
`
`•
`
`•
`
`•
`
`
` ------------------------------ ADVERSE REACTIONS -----------------------------
`Adverse reactions reported in ≥5% of patients treated with ONGLYZA
`•
`and more commonly than in patients treated with placebo are upper
`respiratory tract infection, urinary tract infection, and headache. (6.1)
`Peripheral edema was reported more commonly in patients treated with
`the combination of ONGLYZA and a thiazolidinedione (TZD) than in
`patients treated with the combination of placebo and TZD. (6.1)
`
`
`To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca
`at 1-800- 236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
`
` ------------------------------ DRUG INTERACTIONS ------------------------------
`Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with
`•
`ONGLYZA significantly increases saxagliptin concentrations.
`Recommend limiting ONGLYZA dosage to 2.5 mg once daily. (2.3, 7.1)
`
` ----------------------- USE IN SPECIFIC POPULATIONS ----------------------
`No adequate and well-controlled studies in pregnant women. (8.1)
`•
`
`See 17 for PATIENT COUNSELING INFORMATION and Medication
`Guide
`
`Revised: 8/ 2015
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`1 INDICATIONS AND USAGE
`1.1 Monotherapy and Combination Therapy
`1.2 Limitations of Use
`2 DOSAGE AND ADMINISTRATION
`2.1 Recommended Dosage
`2.2 Dosage in Patients with Renal Impairment
`2.3 Dosage Adjustment with Concomitant Use of Strong CYP3A4/5
`Inhibitors
`2.4 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or
`with Insulin
`3 DOSAGE FORMS AND STRENGTHS
`4 CONTRAINDICATIONS
`5 WARNINGS AND PRECAUTIONS
`5.1 Pancreatitis
`5.2 Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin
`5.3 Hypersensitivity Reactions
`5.4 Severe and Disabling Arthralgia
`5.5 Macrovascular Outcomes
`6 ADVERSE REACTIONS
`6.1 Clinical Trials Experience
`6.2 Postmarketing Experience
`7 DRUG INTERACTIONS
`
`FULL PRESCRIBING INFORMATION
`
`7.1 Strong Inhibitors of CYP3A4/5 Enzymes
`8 USE IN SPECIFIC POPULATIONS
`8.1 Pregnancy
`8.3 Nursing Mothers
`8.4 Pediatric Use
`8.5 Geriatric Use
`10 OVERDOSAGE
`11 DESCRIPTION
`12 CLINICAL PHARMACOLOGY
`12.1 Mechanism of Action
`12.2 Pharmacodynamics
`12.3 Pharmacokinetics
`13 NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`13.2 Animal Toxicology and/or Pharmacology
`14 CLINICAL STUDIES
`14.1 Monotherapy
`14.2 Combination Therapy
`14.3 Renal Impairment
`16 HOW SUPPLIED/STORAGE AND HANDLING
`17 PATIENT COUNSELING INFORMATION
`
`*Sections or subsections omitted from the full prescribing information are not listed.
`
`Reference ID: 3812564
`
`

`

`1 INDICATIONS AND USAGE
`
`1.1 Monotherapy and Combination Therapy
`
`ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
`mellitus in multiple clinical settings [see Clinical Studies (14)].
`
`1.2 Limitation of Use
`ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be
`effective in these settings.
`
`ONGLYZA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of
`pancreatitis are at an increased risk for the development of pancreatitis while using ONGLYZA [see Warnings and
`Precautions (5.1)].
`
`2 DOSAGE AND ADMINISTRATION
`
`2.1 Recommended Dosage
`The recommended dosage of ONGLYZA is 2.5 mg or 5 mg once daily taken regardless of meals. ONGLYZA tablets
`must not be split or cut.
`
`2.2 Dosage in Patients with Renal Impairment
`No dosage adjustment for ONGLYZA is recommended for patients with mild renal impairment (creatinine clearance
`[CrCl] >50 mL/min).
`
`The dosage of ONGLYZA is 2.5 mg once daily (regardless of meals) for patients with moderate or severe renal
`impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (creatinine clearance [CrCl] ≤50 mL/min)
`[see Clinical Pharmacology (12.3) and Clinical Studies (14.3)]. ONGLYZA should be administered following
`hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis.
`
`Because the dosage of ONGLYZA should be limited to 2.5 mg based upon renal function, assessment of renal function is
`recommended prior to initiation of ONGLYZA and periodically thereafter. Renal function can be estimated from serum
`creatinine using the Cockcroft-Gault formula or Modification of Diet in Renal Disease formula [see Clinical
`Pharmacology (12.3)].
`
`Dosage Adjustment with Concomitant Use of Strong CYP3A4/5 Inhibitors
`2.3
`The dosage of ONGLYZA is 2.5 mg once daily when coadministered with strong cytochrome P450 3A4/5 (CYP3A4/5)
`inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,
`saquinavir, and telithromycin) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
`
`Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin
`2.4
`When ONGLYZA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of
`the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia [see Warnings and Precautions
`(5.2)].
`
`3 DOSAGE FORMS AND STRENGTHS
`
`• ONGLYZA (saxagliptin) 5 mg tablets are pink, biconvex, round, film-coated tablets with “5” printed on one side and
`“4215” printed on the reverse side, in blue ink.
`
`Reference ID: 3812564
`
`

`

`• ONGLYZA (saxagliptin) 2.5 mg tablets are pale yellow to light yellow, biconvex, round, film-coated tablets with
`“2.5” printed on one side and “4214” printed on the reverse side, in blue ink.
`
`4 CONTRAINDICATIONS
`
`ONGLYZA is contraindicated in patients with a history of a serious hypersensitivity reaction to ONGLYZA, such as
`anaphylaxis, angioedema, or exfoliative skin conditions [see Warnings and Precautions (5.3) and Adverse Reactions
`(6.2)].
`
`5 WARNINGS AND PRECAUTIONS
`
`5.1 Pancreatitis
`There have been postmarketing reports of acute pancreatitis in patients taking ONGLYZA. After initiation of ONGLYZA,
`patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, ONGLYZA
`should promptly be discontinued and appropriate management should be initiated. It is unknown whether patients with a
`history of pancreatitis are at increased risk for the development of pancreatitis while using ONGLYZA.
`
`5.2 Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin
`When ONGLYZA was used in combination with a sulfonylurea or with insulin, medications known to cause
`hypoglycemia, the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a
`sulfonylurea or with insulin [see Adverse Reactions (6.1)]. Therefore, a lower dose of the insulin secretagogue or insulin
`may be required to minimize the risk of hypoglycemia when used in combination with ONGLYZA [see Dosage and
`Administration (2.4)].
`
`5.3 Hypersensitivity Reactions
`There have been postmarketing reports of serious hypersensitivity reactions in patients treated with ONGLYZA. These
`reactions include anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the
`first 3 months after initiation of treatment with ONGLYZA, with some reports occurring after the first dose. If a serious
`hypersensitivity reaction is suspected, discontinue ONGLYZA, assess for other potential causes for the event, and
`institute alternative treatment for diabetes [see Adverse Reactions (6.2)].
`
`Use caution in a patient with a history of angioedema to another dipeptidyl peptidase-4 (DPP4) inhibitor because it is
`unknown whether such patients will be predisposed to angioedema with ONGLYZA.
`
`5.4 Severe and Disabling Arthralgia
`There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP4 inhibitors. The time to
`onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of
`symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when
`restarting the same drug or a different DPP4 inhibitor. Consider DPP4 inhibitors as a possible cause for severe joint pain
`and discontinue drug if appropriate.
`
`5.5 Macrovascular Outcomes
`There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or
`any other antidiabetic drug.
`
`Reference ID: 3812564
`
`

`

`6 ADVERSE REACTIONS
`
`6.1 Clinical Trials Experience
`Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials
`of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed
`in practice.
`
`Adverse Reactions with Monotherapy and with Add-On Combination Therapy
`
`In two placebo-controlled monotherapy trials of 24-weeks duration, patients were treated with ONGLYZA 2.5 mg daily,
`ONGLYZA 5 mg daily, and placebo. Three 24-week, placebo-controlled, add-on combination therapy trials were also
`conducted: one with metformin, one with a thiazolidinedione (pioglitazone or rosiglitazone), and one with glyburide. In
`these three trials, patients were randomized to add-on therapy with ONGLYZA 2.5 mg daily, ONGLYZA 5 mg daily, or
`placebo. A saxagliptin 10 mg treatment arm was included in one of the monotherapy trials and in the add-on combination
`trial with metformin. The 10 mg dosage is not an approved dosage.
`
`In a prespecified pooled analysis of the 24-week data (regardless of glycemic rescue) from the two monotherapy trials, the
`add-on to metformin trial, the add-on to thiazolidinedione (TZD) trial, and the add-on to glyburide trial, the overall
`incidence of adverse events in patients treated with ONGLYZA 2.5 mg and ONGLYZA 5 mg was similar to placebo
`(72% and 72.2% versus 70.6%, respectively). Discontinuation of therapy due to adverse events occurred in 2.2%, 3.3%,
`and 1.8% of patients receiving ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo, respectively. The most common
`adverse events (reported in at least 2 patients treated with ONGLYZA 2.5 mg or at least 2 patients treated with
`ONGLYZA 5 mg) associated with premature discontinuation of therapy included lymphopenia (0.1% and 0.5% versus
`0%, respectively), rash (0.2% and 0.3% versus 0.3%), blood creatinine increased (0.3% and 0% versus 0%), and blood
`creatine phosphokinase increased (0.1% and 0.2% versus 0%). The adverse reactions in this pooled analysis reported
`(regardless of investigator assessment of causality) in ≥5% of patients treated with ONGLYZA 5 mg, and more
`commonly than in patients treated with placebo are shown in Table 1.
`
`Table 1: Adverse Reactions in Placebo-Controlled Trials* Reported in ≥5% of Patients Treated with
`ONGLYZA 5 mg and More Commonly than in Patients Treated with Placebo
`
`
`
`
`
`Upper respiratory tract infection
`
`Urinary tract infection
`
`Headache
`
`Number (%) of Patients
`
`ONGLYZA 5 mg
`N=882
`
`68 (7.7)
`
`60 (6.8)
`
`57 (6.5)
`
`Placebo
`N=799
`
`61 (7.6)
`
`49 (6.1)
`
`47 (5.9)
`
`* The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following:
`metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue).
`
`
`In patients treated with ONGLYZA 2.5 mg, headache (6.5%) was the only adverse reaction reported at a rate ≥5% and
`more commonly than in patients treated with placebo.
`
`In this pooled analysis, adverse reactions that were reported in ≥2% of patients treated with ONGLYZA 2.5 mg or
`ONGLYZA 5 mg and ≥1% more frequently compared to placebo included: sinusitis (2.9% and 2.6% versus 1.6%,
`
`Reference ID: 3812564
`
`

`

`respectively), abdominal pain (2.4% and 1.7% versus 0.5%), gastroenteritis (1.9% and 2.3% versus 0.9%), and vomiting
`(2.2% and 2.3% versus 1.3%).
`
`In the add-on to TZD trial, the incidence of peripheral edema was higher for ONGLYZA 5 mg versus placebo (8.1% and
`4.3%, respectively). The incidence of peripheral edema for ONGLYZA 2.5 mg was 3.1%. None of the reported adverse
`reactions of peripheral edema resulted in study drug discontinuation. Rates of peripheral edema for ONGLYZA 2.5 mg
`and ONGLYZA 5 mg versus placebo were 3.6% and 2% versus 3% given as monotherapy, 2.1% and 2.1% versus 2.2%
`given as add-on therapy to metformin, and 2.4% and 1.2% versus 2.2% given as add-on therapy to glyburide.
`
`The incidence rate of fractures was 1.0 and 0.6 per 100 patient-years, respectively, for ONGLYZA (pooled analysis of 2.5
`mg, 5 mg, and 10 mg) and placebo. The 10 mg dosage is not an approved dosage. The incidence rate of fracture events in
`patients who received ONGLYZA did not increase over time. Causality has not been established and nonclinical studies
`have not demonstrated adverse effects of ONGLYZA on bone.
`
`An event of thrombocytopenia, consistent with a diagnosis of idiopathic thrombocytopenic purpura, was observed in the
`clinical program. The relationship of this event to ONGLYZA is not known.
`
`Adverse Reactions in Patients with Renal Impairment
`ONGLYZA 2.5 mg was compared to placebo in a 12-week trial in 170 patients with type 2 diabetes and moderate or
`severe renal impairment or end-stage renal disease (ESRD). The incidence of adverse events, including serious adverse
`events and discontinuations due to adverse events, was similar between ONGLYZA and placebo.
`
`Adverse Reactions with Concomitant Use with Insulin
`In the add-on to insulin trial [see Clinical Studies (14.2)], the incidence of adverse events, including serious adverse
`events and discontinuations due to adverse events, was similar between ONGLYZA and placebo, except for confirmed
`hypoglycemia [see Adverse Reactions (6.1)].
`
`Adverse Reactions with Concomitant Use with Metformin in Treatment-Naive Patients with Type 2 Diabetes
`Table 2 shows the adverse reactions reported (regardless of investigator assessment of causality) in ≥5% of patients
`participating in an additional 24-week, active-controlled trial of coadministered ONGLYZA and metformin in treatment-
`naive patients
`
`Table 2: Initial Therapy with Combination of ONGLYZA and Metformin in Treatment-Naive Patients:
`Adverse Reactions Reported in ≥5% of Patients Treated with Combination Therapy of ONGLYZA 5 mg
`Plus Metformin (and More Commonly than in Patients Treated with Metformin Alone)
`
`
`
`
`Number (%) of Patients
`Metformin*
`ONGLYZA 5 mg +
`Metformin*
`N=328
`N=320
`17 (5.2)
`24 (7.5)
`Headache
`13 (4.0)
`22 (6.9)
`Nasopharyngitis
`* Metformin was initiated at a starting dose of 500 mg daily and titrated up to a maximum of 2000 mg daily.
`
`Hypoglycemia
`Adverse reactions of hypoglycemia were based on all reports of hypoglycemia. A concurrent glucose measurement was
`not required or was normal in some patients. Therefore, it is not possible to conclusively determine that all these reports
`reflect true hypoglycemia.
`
`Reference ID: 3812564
`
`

`

`In the add-on to glyburide study, the overall incidence of reported hypoglycemia was higher for ONGLYZA 2.5 mg and
`ONGLYZA 5 mg (13.3% and 14.6%) versus placebo (10.1%). The incidence of confirmed hypoglycemia in this study,
`defined as symptoms of hypoglycemia accompanied by a fingerstick glucose value of ≤50 mg/dL, was 2.4% and 0.8% for
`ONGLYZA 2.5 mg and ONGLYZA 5 mg and 0.7% for placebo [see Warnings and Precautions (5.2)]. The incidence of
`reported hypoglycemia for ONGLYZA 2.5 mg and ONGLYZA 5 mg versus placebo given as monotherapy was 4% and
`5.6% versus 4.1%, respectively, 7.8% and 5.8% versus 5% given as add-on therapy to metformin, and 4.1% and 2.7%
`versus 3.8% given as add-on therapy to TZD. The incidence of reported hypoglycemia was 3.4% in treatment-naive
`patients given ONGLYZA 5 mg plus metformin and 4% in patients given metformin alone.
`
`In the active-controlled trial comparing add-on therapy with ONGLYZA 5 mg to glipizide in patients inadequately
`controlled on metformin alone, the incidence of reported hypoglycemia was 3% (19 events in 13 patients) with
`ONGLYZA 5 mg versus 36.3% (750 events in 156 patients) with glipizide. Confirmed symptomatic hypoglycemia
`(accompanying fingerstick blood glucose ≤50 mg/dL) was reported in none of the ONGLYZA-treated patients and in 35
`glipizide-treated patients (8.1%) (p<0.0001).
`
`During 12 weeks of treatment in patients with moderate or severe renal impairment or ESRD, the overall incidence of
`reported hypoglycemia was 20% among patients treated with ONGLYZA 2.5 mg and 22% among patients treated with
`placebo. Four ONGLYZA-treated patients (4.7%) and three placebo-treated patients (3.5%) reported at least one episode
`of confirmed symptomatic hypoglycemia (accompanying fingerstick glucose ≤50 mg/dL).
`
`In the add-on to insulin trial, the overall incidence of reported hypoglycemia was 18.4% for ONGLYZA 5 mg and 19.9%
`for placebo. However, the incidence of confirmed symptomatic hypoglycemia (accompanying fingerstick blood glucose
`≤50 mg/dL) was higher with ONGLYZA 5 mg (5.3%) versus placebo (3.3%).
`
`In the add-on to metformin plus sulfonylurea trial, the overall incidence of reported hypoglycemia was 10.1% for
`ONGLYZA 5 mg and 6.3% for placebo. Confirmed hypoglycemia was reported in 1.6% of the ONGLYZA-treated
`patients and in none of the placebo-treated patients [see Warnings and Precautions (5.2)].
`
`Hypersensitivity Reactions
`Hypersensitivity-related events, such as urticaria and facial edema in the 5-study pooled analysis up to Week 24 were
`reported in 1.5%, 1.5%, and 0.4% of patients who received ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo,
`respectively. None of these events in patients who received ONGLYZA required hospitalization or were reported as life-
`threatening by the investigators. One ONGLYZA-treated patient in this pooled analysis discontinued due to generalized
`urticaria and facial edema.
`
`Infections
`In the unblinded, controlled, clinical trial database for ONGLYZA to date, there have been 6 (0.12%) reports of
`tuberculosis among the 4959 ONGLYZA-treated patients (1.1 per 1000 patient-years) compared to no reports of
`tuberculosis among the 2868 comparator-treated patients. Two of these six cases were confirmed with laboratory testing.
`The remaining cases had limited information or had presumptive diagnoses of tuberculosis. None of the six cases occurred
`in the United States or in Western Europe. One case occurred in Canada in a patient originally from Indonesia who had
`recently visited Indonesia. The duration of treatment with ONGLYZA until report of tuberculosis ranged from 144 to 929
`days. Post-treatment lymphocyte counts were consistently within the reference range for four cases. One patient had
`lymphopenia prior to initiation of ONGLYZA that remained stable throughout ONGLYZA treatment. The final patient
`had an isolated lymphocyte count below normal approximately four months prior to the report of tuberculosis. There have
`been no spontaneous reports of tuberculosis associated with ONGLYZA use. Causality has not been estimated and there
`are too few cases to date to determine whether tuberculosis is related to ONGLYZA use.
`
`There has been one case of a potential opportunistic infection in the unblinded, controlled clinical trial database to date in
`an ONGLYZA-treated patient who developed suspected foodborne fatal salmonella sepsis after approximately 600 days
`
`Reference ID: 3812564
`
`

`

`of ONGLYZA therapy. There have been no spontaneous reports of opportunistic infections associated with ONGLYZA
`use.
`
`Vital Signs
`No clinically meaningful changes in vital signs have been observed in patients treated with ONGLYZA.
`
`Laboratory Tests
`
`Absolute Lymphocyte Counts
`There was a dose-related mean decrease in absolute lymphocyte count observed with ONGLYZA. From a baseline mean
`absolute lymphocyte count of approximately 2200 cells/microL, mean decreases of approximately 100 and 120
`cells/microL with ONGLYZA 5 mg and 10 mg, respectively, relative to placebo were observed at 24 weeks in a pooled
`analysis of five placebo-controlled clinical studies. Similar effects were observed when ONGLYZA 5 mg was given in
`initial combination with metformin compared to metformin alone. There was no difference observed for ONGLYZA 2.5
`mg relative to placebo. The proportion of patients who were reported to have a lymphocyte count ≤750 cells/microL was
`0.5%, 1.5%, 1.4%, and 0.4% in the ONGLYZA 2.5 mg, 5 mg, 10 mg, and placebo groups, respectively. In most patients,
`recurrence was not observed with repeated exposure to ONGLYZA although some patients had recurrent decreases upon
`rechallenge that led to discontinuation of ONGLYZA. The decreases in lymphocyte count were not associated with
`clinically relevant adverse reactions. The 10 mg dosage is not an approved dosage.
`
`The clinical significance of this decrease in lymphocyte count relative to placebo is not known. When clinically indicated,
`such as in settings of unusual or prolonged infection, lymphocyte count should be measured. The effect of ONGLYZA on
`lymphocyte counts in patients with lymphocyte abnormalities (e.g., human immunodeficiency virus) is unknown.
`
`Postmarketing Experience
`6.2
`Additional adverse reactions have been identified during postapproval use of ONGLYZA. Because these
`reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably
`estimate their frequency or establish a causal relationship to drug exposure.
`
`• Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions [see
`Contraindications (4) and Warnings and Precautions (5.3)].
`
`• Acute pancreatitis [see Indications and Usage (1.2) and Warnings and Precautions (5.1)].
`• Severe and disabling arthralgia [see Warnings and Precautions (5.4)].
`
`7 DRUG INTERACTIONS
`
`Strong Inhibitors of CYP3A4/5 Enzymes
`7.1
`Ketoconazole significantly increased saxagliptin exposure. Similar significant increases in plasma concentrations of
`saxagliptin are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin, indinavir,
`itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). The dose of ONGLYZA should be limited
`to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor [see Dosage and Administration (2.3) and Clinical
`Pharmacology (12.3)].
`
`Reference ID: 3812564
`
`

`

`8 USE IN SPECIFIC POPULATIONS
`
`8.1 Pregnancy
`
`Pregnancy Category B
`There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not
`always predictive of human response, ONGLYZA, like other antidiabetic medications, should be used during pregnancy
`only if clearly needed.
`
`Saxagliptin was not teratogenic at any dose tested when administered to pregnant rats and rabbits during periods of
`organogenesis. Incomplete ossification of the pelvis, a form of developmental delay, occurred in rats at a dose of 240
`mg/kg, or approximately 1503 and 66 times human exposure to saxagliptin and the active metabolite, respectively, at the
`maximum recommended human dose (MRHD) of 5 mg. Maternal toxicity and reduced fetal body weights were observed
`at 7986 and 328 times the human exposure at the MRHD for saxagliptin and the active metabolite, respectively. Minor
`skeletal variations in rabbits occurred at a maternally toxic dose of 200 mg/kg, or approximately 1432 and 992 times the
`MRHD.
`
`Coadministration of saxagliptin and metformin, to pregnant rats and rabbits during the period of organogenesis, was
`neither embryolethal nor teratogenic in either species when tested at doses yielding systemic exposures (AUC) up to 100
`and 10 times the MRHD (saxagliptin 5 mg and metformin 2000 mg), respectively, in rats; and 249 and 1.1 times the
`MRHDs in rabbits. In rats, minor developmental toxicity was limited to an increased incidence of wavy ribs; associated
`maternal toxicity was limited to weight decrements of 11% to 17% over the course of the study, and related reductions in
`maternal food consumption. In rabbits, coadministration was poorly tolerated in a subset of mothers (12 of 30), resulting
`in death, moribundity, or abortion. However, among surviving mothers with evaluable litters, maternal toxicity was
`limited to marginal reductions in body weight over the course of gestation days 21 to 29; and associated developmental
`toxicity in these litters was limited to fetal body weight decrements of 7%, and a low incidence of delayed ossification of
`the fetal hyoid.
`
`Saxagliptin administered to female rats from gestation day 6 to lactation day 20 resulted in decreased body weights in
`male and female offspring only at maternally toxic doses (exposures ≥1629 and 53 times saxagliptin and its active
`metabolite at the MRHD). No functional or behavioral toxicity was observed in offspring of rats administered saxagliptin
`at any dose.
`
`Saxagliptin crosses the placenta into the fetus following dosing in pregnant rats.
`
`8.3 Nursing Mothers
`Saxagliptin is secreted in the milk of lactating rats at approximately a 1:1 ratio with plasma drug concentrations. It is not
`known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should be
`exercised when ONGLYZA is administered to a nursing woman.
`
`8.4 Pediatric Use
`Safety and effectiveness of ONGLYZA in pediatric patients under 18 years of age have not been established.
`Additionally, studies characterizing the pharmacokinetics of ONGLYZA in pediatric patients have not been performed.
`
`8.5 Geriatric Use
`In the six, double-blind, controlled clinical safety and efficacy trials of ONGLYZA, 634 (15.3%) of the 4148 randomized
`patients were 65 years and over, and 59 (1.4%) patients were 75 years and over. No overall differences in safety or
`effectiveness were observed between patients ≥65 years old and the younger patients. While this clinical experience has
`not identified differences in responses between the elderly and younger patients, greater sensitivity of some older
`individuals cannot be ruled out.
`
`Reference ID: 3812564
`
`

`

`Saxagliptin and its active metabolite are eliminated in part by the kidney. Because elderly patients are more likely to have
`decreased renal function, care should be taken in dose selection in the elderly based on renal function [see Dosage and
`Administration (2.2) and Clinical Pharmacology (12.3)].
`
`10 OVERDOSAGE
`
`In a controlled clinical trial, once-daily, orally-administered ONGLYZA in healthy subjects at doses up to 400 mg daily
`for 2 weeks (80 times the MRHD) had no dose-related clinical adverse reactions and no clinically meaningful effect on
`QTc interval or heart rate.
`
`In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
`Saxagliptin and its active metabolite are removed by hemodialysis (23% of dose over 4 hours).
`
`11 DESCRIPTION
`
`Saxagliptin is an orally-active inhibitor of the DPP4 enzyme.
`Saxagliptin monohydrate is described chemically as (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-
`yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, monohydrate or (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-
`hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrate. The empirical formula is
`C18H25N3O2•H2O and the molecular weight is 333.43. The structural formula is:
`
`
`
`Saxagliptin monohydrate is a white to light yellow or light brown, non-hygroscopic, crystalline powder. It is sparingly
`soluble in water at 24°C ± 3°C, slightly soluble in ethyl acetate, and soluble in methanol, ethanol, isopropyl alcohol,
`acetonitrile, acetone, and polyethylene glycol 400 (PEG 400).
`
`Each film-coated tablet of ONGLYZA for oral use contains either 2.79 mg saxagliptin hydrochloride (anhydrous)
`equivalent to 2.5 mg saxagliptin or 5.58 mg saxagliptin hydrochloride (anhydrous) equivalent to 5 mg saxagliptin and the
`following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium
`stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, polyethylene glycol,
`titanium dioxide, talc, and iron oxides.
`
`12 CLINICAL PHARMACOLOGY
`
`12.1 Mechanism of Action
`Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent
`insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These
`hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the
`DPP4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic
`glucose production. In patients with type 2 diabetes, concentrations of GLP-1 are reduced but the insulin response to
`
`Reference ID: 3812564
`
`

`

`GLP-1 is preserved. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones,
`thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a
`glucose-dependent manner in patients with type 2 diabetes mellitus.
`
`12.2 Pharmacodynamics
`In patients with type 2 diabetes mellitus, administration of ONGLYZA inhibits DPP4 enzyme activity for a 24-hour
`period. After an oral glucose load or a meal, this DPP4 inhibition resulted in a 2- to 3-fold increase in circulating levels of
`active GLP-1 and GIP, decreased glucagon concentrations, and increased glucose-dependent insulin se

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket